COMPANY PROFILE

About FIBREX Medical

FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases.

The company aims to become a leader in the development and commercialisation of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction.

FIBREX Medical has identified several peptides and peptide analogs adressing these pathomechanisms. They potently inhibit acute inflammatory reactions and prevent capillary leak via a novel mechanism of action. The most advanced product of FIBREX Medical – FX06 – prevents reperfusion injury after myocardial infarction as well as organ tranplantation and aims at markets with more than 5,000,000 potential patients per year in the Western World.